New Data Presented at DDW 2022 Shows Nearly Two-Fold Risk of Loss of Remission in Ulcerative Colitis Patients who had Histologic Inflammation on Baseline Biopsy
Target RWE's IBD study & real world data presented at DDW 2022 included more than 500 patients with Ulcerative Colitis.
- Target RWE's IBD study & real world data presented at DDW 2022 included more than 500 patients with Ulcerative Colitis.
- The study found that among patients in endoscopic remission, histologic inflammation was associated with a two-fold increased risk of subsequent LOR.
- "We sought to uncover factors predictive of relapse and found histologic inflammation despite endoscopic remission to be an important risk factor for subsequent LOR.
- Future research should focus on determining if treatment modification or intensification may be effective at preventing LOR in certain patients."